Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 May;35(5):702-11. Erratum in: Exp Hematol. 2007 Sep;35(9):1476.

PMID:
17577920
2.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
4.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
5.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
6.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
7.
8.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
9.

JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.

Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H.

Ann Hematol. 2007 Nov;86(11):793-800. Epub 2007 Aug 9. Review.

PMID:
17687555
10.
11.
12.

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M.

Thromb Res. 2009 Sep;124(4):409-17. doi: 10.1016/j.thromres.2009.02.004. Epub 2009 Mar 18. Review.

PMID:
19299003
13.

Essential thrombocythemia: scientific advances and current practice.

Tefferi A.

Curr Opin Hematol. 2006 Mar;13(2):93-8. Review.

PMID:
16456375
14.

Essential thrombocythemia: a review of diagnostic and pathologic features.

Sanchez S, Ewton A.

Arch Pathol Lab Med. 2006 Aug;130(8):1144-50. Review.

PMID:
16879015

Supplemental Content

Support Center